The T-42 (also known as the TG-V) was a Soviet super-heavy tank project of the interwar period. It was developed in 1932 by the OKB -5 design bureau at Bolshevik Plant no. 232 under the direction of a German engineer-designer Edward Grote [de; ru]. Development did not advance past the stage of construction drawings and scale models.

2023年5月23日 · 该研究评价了在中国卒中患者人群中，使用0.25 mg/kg TNK对比标准剂量rt-PA静脉溶栓的安全性和有效性，结果与国际多项研究一致。 另外，对于大血管闭塞且发病6 h内的卒中患者，使用TNK替代rt-PA静脉溶栓是否能获得更好的再灌注水平和血管再通率？

2020年10月13日 · The TAAIS (Tenecteplase versus Alteplase for Acute Ischaemic Stroke), also referred to as the Australian-TNK trial, randomized patients with middle cerebral artery occlusion on computed tomography angiography and penumbral mismatch on computed tomography (CT) perfusion to 0.1 or 0.25 mg/kg tenecteplase (n=25 per group) and observed ...

2024年11月12日 · The updated meta-analysis confirms similar safety between TNK 0.25 mg/kg and TPA, while showing that TNK is superior to TPA regarding excellent functional outcome and reduced disability at 3 months. These findings support transitioning to TNK in clinical practice.

替奈普酶（TNK）是一种从阿替普酶（rt-PA）衍生的基因工程药物。 其半衰期较长，可通过推注快速给药，与 rt-PA 相比具有后勤优势。 此外，TNK 对纤溶酶原激活剂抑制剂-1 失活的抵抗力增强，从而更有效地溶解富含血小板的凝块。

Tenecteplase (TNK), as a thrombolytic treatment for acute ischemic stroke (AIS), has been found to be effective when used within 4.5 hours of symptom onset. However, the efficacy of TNK after 4.5 hours is not well established, especially in patients with large vessel occlusion and with no …

Outcome data regarding the administration of tenecteplase (TNK) to acute ischemic stroke (AIS) patients presenting in the extended time window are limited. We aimed to assess the current evidence regarding the efficacy and safety of TNK at a dose of 0.25 mg/kg for AIS treatment in the extended time window.

2024年9月13日 · 研究结果显示，对于发病4.5小时静脉溶栓窗内的急性缺血性卒中患者，使用替奈普酶（tnk）在90天时的良好功能结局方面不劣于阿替普酶，且安全性相似。

2025年1月13日 · Our initial data suggest that TNK may be safe in childhood arterial ischemic stroke. Strategically designed prospective studies are needed to further define safety, optimal dosage, and efficacy of TNK in acute pediatric stroke.

2024年8月26日 · However, the latest 2023 European Stroke Organisation Guideline strongly recommended that tenecteplase 0.25 mg/kg can be used as a safe and effective alternative to alteplase 0.9 mg/kg for patients with AIS or large vessel occlusion AIS within 4.5 hours of onset based on a moderate quality of evidence. 7 The latest phase III Tenecteplase in Pati...